Terms and Conditions

BY USING THIS SITE YOU ACKNOWLEDGE THAT GENENTECH, INC. AND BIOGEN IDEC, INC. ARE PROVIDING THE MATERIAL FOR INFORMATIONAL PURPOSES ONLY AND THAT GENENTECH, INC. AND BIOGEN IDEC, INC. AND THEIR AGENTS, AFFILIATES, PARTNERS OR LICENSORS ARE PROVIDING THE MATERIALS TO YOU FOR THE PURPOSES OF GIVING YOU MEDICAL ADVICE. YOU SHOULD NOT RELY ON THE MATERIALS IN DECIDING ON A TREATMENT PLAN, DRUG USAGE, OR ANY OTHER MEDICAL ADVICE REGARDING THE MATERIALS, AND GENENTECH, INC. AND BIOGEN IDEC, INC. AND THEIR LICENSORS STRONGLY URGE THAT PATIENTS CONSULT WITH A PHYSICIAN IN CONNECTION WITH ANY AND ALL TREATMENT OPTIONS THAT MAY BE AVAILABLE.

BY USING THIS WEBSITE, YOU ACCEPT THE INFORMATION, PRODUCTS AND SERVICES PROVIDED HEREIN AS IS. NEITHER GENENTECH, INC. NOR BIOGEN IDEC, INC. MAKE ANY EXPRESS OR IMPLIED WARRANTY REGARDING THE ACCURACY, CONTENT, COMPLETENESS, RELIABILITY, OPERABILITY OR LEGALITY OF INFORMATION CONTAINED WITHIN THIS WEBSITE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF PROPRIETARY RIGHTS.

IN NO EVENT SHALL GENENTECH, INC. OR BIOGEN IDEC, INC. OR THEIR AGENTS, AFFILIATES, PARTNERS OR LICENSORS BE LIABLE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR ANY DAMAGES WHATSOEVER RESULTING FROM LOSS RELATED TO THE USE OF OUR WEBSITES, WHETHER IN AN ACTION OF CONTRACT, BREACH OF WARRANTY, NEGLIGENCE OR OTHER TORTIOUS ACTION ARISING OUT OF OR IN CONNECTION WITH THE USE OF THE MATERIALS CONTAINED ON THIS SITE.

Rituxan (Rituximab) INDICATIONS AND USAGE

Non-Hodgkin's Lymphoma (NHL)

Rituxan® is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

Rituxan Boxed WARNINGS and Additional Important Safety Information

The most important serious adverse reactions of Rituxan are fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation with fulminant hepatitis, other viral infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation. The most common adverse reactions of Rituxan (incidence ≥25%) observed in patients with NHL are infusion reactions, fever, chills, infection, asthenia, and lymphopenia. The most common adverse reactions of Rituxan observed in patients with RA are hypertension, nausea, upper respiratory tract infection, arthralgia, pruritus, and pyrexia.

Attention healthcare provider: Provide Medication Guide to patient prior to Rituxan infusion.

For additional safety information, please see the full prescribing information, including Boxed WARNINGS and Medication Guide.